CEO of Biomarin Pharmaceutical Inc (30-Year Financial, Insider Trades) Jean Jacques Bienaime (insider trades) sold 14,000 shares of BMRN on 03/12/2021 at an average price of $77.39 a share. The total sale was $1.1 million.
Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. Biomarin Pharmaceutical Inc has a market cap of $14.25 billion; its shares were traded at around $78.390000 with a P/E ratio of 17.77 and P/S ratio of 7.88.
CEO Recent Trades:
- CEO Jean Jacques Bienaime sold 14,000 shares of BMRN stock on 03/12/2021 at the average price of $77.39. The price of the stock has increased by 1.29% since.
- CEO Jean Jacques Bienaime sold 7,000 shares of BMRN stock on 02/19/2021 at the average price of $83.58. The price of the stock has decreased by 6.21% since.
- CEO Jean Jacques Bienaime sold 7,000 shares of BMRN stock on 02/18/2021 at the average price of $85.08. The price of the stock has decreased by 7.86% since.
- CEO Jean Jacques Bienaime sold 8,000 shares of BMRN stock on 02/17/2021 at the average price of $84.54. The price of the stock has decreased by 7.27% since.
Directors and Officers Recent Trades:
- Director Michael G Grey sold 5,000 shares of BMRN stock on 03/05/2021 at the average price of $76.28. The price of the stock has increased by 2.77% since.
- Director V Bryan Lawlis sold 7,500 shares of BMRN stock on 02/16/2021 at the average price of $87.41. The price of the stock has decreased by 10.32% since.
For the complete insider trading history of BMRN, click here
.
